(Reuters) Shares of Novavax rose more than 10% in pre-market on Monday on reports that it will begin deliveries of Covid-19 vaccines in the EU in the first quarter of 2022.
Dubbed Nuvaxovid, the Novavax’s two-dose vaccine would be the fifth shot in the EU upon approval.
Novavax had, earlier in the year, committed to delivering small shipments of the vaccine to the EU by the end of the year, which was expected to be increased in 2022.
The biotech company had signed a contract, in August, for about 200 million Covid-19 vaccine doses for deliveries to the EU. Half of the doses were optional for the company.
NVAX: NASDAQ is up +10.11% on premarket.
